Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

Updated results from the phase 2 REACH1 trial, presented at the 2018 American Society of Hematology Annual Meeting, which analyzed ruxolitinib plus corticosteroids in patients with hematologic malignancies who acquired steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplant, demonstrated overall responses in 54.9% of patients by Day 28.

Blood (ASH Abstract)